Engineered immune cells take aim at multiple myeloma from multiple angles

NCT ID NCT03271632

Recruiting now Disease control Sponsor: Shenzhen Geno-Immune Medical Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new type of immunotherapy called CAR T cells that are designed to recognize several different targets on multiple myeloma cancer cells. The treatment involves taking a patient's own immune cells, modifying them in a lab to better attack the cancer, and infusing them back. The trial includes 20 adults with relapsed or refractory multiple myeloma who have limited options left. Researchers are checking whether the treatment is safe and how long the modified cells persist in the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CAR T cells targeting multiple cancer antigens
What this could lead to: If successful, this approach could offer a new treatment option for patients with multiple myeloma who have run out of standard therapies.
What could go wrong: This is an early-phase trial with a small number of participants, so results may not apply broadly. CAR T cell therapy can cause serious side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Shenzhen Geno-immune Medical Institute
RECRUITING

Shenzhen, Guangdong, 518000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.